Recent advances in vaccine and immunotherapy for COVID-19

Rabaan, Ali A.; Al-Ahmed, Shamsah H.; Sah, Ranjit; Al‐Tawfiq, Jaffar A.; Al-Qaaneh, Ayman M.; Al-Jamea, Lamiaa H.; Woodman, Alexander; Al-Qahtani, Manaf; Haque, Shafiul; Harapan, Harapan; Bonilla-Aldana, D. Katterine; Kumar, Pavan; Dhama, Kuldeep; Rodríguez‐Morales, Alfonso J.

doi:10.1080/21645515.2020.1825896

Cited by 40 publications

(34 citation statements)

References 48 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Through the Access to COVID-19 Tools (ACT) Accelerator, WHO works in partnership with scientists, industry, and global health organizations to speed up the pandemic response. COVAX (led by the WHO, the Global Alliance for Vaccines and Immunization [GAVI] and the Coalition for Disease Preparedness Innovations [CEPI]) will promote the equal access and distribution of these vaccines to protect citizens in all countries when a safe and efficient vaccine is developed and people who are most at risk will be given first priority on vaccination ( Sharma et al., 2020 ; Rabaan et al., 2020 ).…”

Section: Preventions and Treatment Of Covid-19mentioning

confidence: 99%

The COVID-19 pandemic face mask waste: A blooming threat to the marine environment

et al. 2021

View full text Add to dashboard Cite

Section: Preventions and Treatment Of Covid-19mentioning

confidence: 99%

The COVID-19 pandemic face mask waste: A blooming threat to the marine environment

et al. 2021

View full text Add to dashboard Cite

“…Since the start of the pandemic, there have been incredible efforts to study coronavirus disease 2019 (COVID- 19), including public health prevention [1], advancing diagnostic capabilities [2], treatment and vaccine development [3], and understanding the broad spectrum of disease sequelae [4]. While researchers and pharmaceutical industries are currently racing for the development of effective antiviral medications and vaccines, research in the medical management of COVID-19 has also expanded tremendously [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19

et al. 2021

View full text Add to dashboard Cite

Background Research surrounding COVID-19 (coronavirus disease 2019) is rapidly increasing, including the study of biomarkers for predicting outcomes. There is little data examining the correlation between serum albumin levels and COVID-19 disease severity. The purpose of this study is to evaluate whether admission albumin levels reliably predict outcomes in COVID-19 patients. Methods We retrospectively reviewed 181 patients from two hospitals who had COVID-19 pneumonia confirmed by polymerase chain reaction (PCR) testing and radiologic imaging, who were hospitalized between March and July 2020. We recorded demographics, COVID-19 testing techniques, and day of admission labs. The outcomes recorded included the following: venous thromboembolism (VTE), acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, discharge with new or higher home oxygen supplementation, readmission within 90 days, in-hospital mortality, and total adverse events. A multivariate modified Poisson regression analysis was then performed to determine significant predictors for increased adverse events in patients with COVID-19 pneumonia. Results A total of 109 patients (60.2%) had hypoalbuminemia (albumin level < 3.3 g/dL). Patients with higher albumin levels on admission had a 72% decreased risk of developing venous thromboembolism (adjusted relative risk [RR]:0.28, 95% confidence interval [CI]:0.14–0.53, p<0.001) for every 1 g/dL increase of albumin. Moreover, higher albumin levels on admission were associated with a lower risk of developing ARDS (adjusted RR:0.73, 95% CI:0.55–0.98, p = 0.033), admission to the ICU (adjusted RR:0.64, 95% CI:0.45–0.93, p = 0.019), and were less likely to be readmitted within 90 days (adjusted RR:0.37, 95% CI:0.17–0.81, p = 0.012). Furthermore, higher albumin levels were associated with fewer total adverse events (adjusted RR:0.65, 95% CI:0.52–0.80, p<0.001). Conclusions Admission serum albumin levels appear to be a predictive biomarker for outcomes in COVID-19 patients. We found that higher albumin levels on admission were associated with significantly fewer adverse outcomes, including less VTE events, ARDS development, ICU admissions, and readmissions within 90 days. Screening patients may lead to early identification of patients at risk for developing in-hospital complications and improve optimization and preventative efforts in this cohort.

show abstract

“…Currently, multiple countries have begun their national COVID-19 vaccination programs using only one type of vaccine [ 30 ]. Given the mentioned considerations, using different vaccines from various biotechnological approaches (e.g., mRNA, viral vectors, inactivated virus) would be suitable for distinct epidemiological scenarios [ 31 , 32 ]. Finally, even in developed countries, the current dilemma is the lack of enough vaccines to supply the governments for their application.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccination campaign in Nepal, emerging UK variant and futuristic vaccination strategies to combat the ongoing pandemic

Sah

Khatiwada

Shrestha

et al. 2021

Travel Medicine and Infectious Disease

Self Cite

View full text Add to dashboard Cite

With the emergence of the new variants of concern (VOC) of the SARS-CoV-2, the efficacy of certain vaccines against them requires further research and considerations for future scenarios of COVID-19 vaccination. The vaccines' lack of efficacy against VOC will pose at risk to the vaccinated population and is a public health threat. In this commentary, we discuss Nepal's recent experiences and expectations regarding the confirmation of VOC B.1.1.7 from the United Kingdom in the country.

show abstract

Recent advances in vaccine and immunotherapy for COVID-19

Cited by 40 publications

References 48 publications

The COVID-19 pandemic face mask waste: A blooming threat to the marine environment

The COVID-19 pandemic face mask waste: A blooming threat to the marine environment

Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19

COVID-19 vaccination campaign in Nepal, emerging UK variant and futuristic vaccination strategies to combat the ongoing pandemic

Contact Info

Product

Resources

About